CRISPR Therapeutics AG's General Counsel and Secretary just cashed-in 27,500 options

James R. Kasinger, CRISPR Therapeutics AG's General Counsel and Secretary, recently cashed-in 27,500 options. The options were exercised at $51.49, while the disposals took place between $203.58 and $207.61 per share, on January 19, 2021. Kasinger continues to hold 22,431 shares of the company. Kasinger operates out of Cambridge, MA. Some additional info was provided as follows:


Includes 16 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.00 to $203.95, inclusive. The repo rting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.00 to $204.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.00 to $205.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.00 to $206.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.39 to $208.1050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option was granted on March 7, 2018 with respect to 40,000 Common Shares and vests in 48 equal monthly installments.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever CRISPR Therapeutics AG makes a similar move, sign up!

Other recent filings from the company include the following:

CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 30,000 options - June 17, 2021
CRISPR Therapeutics AG director just disposed of 10,000 shares - June 15, 2021
Statement of changes in beneficial ownership of securities - June 14, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021

Auto Refresh

Feedback